Description

Simple

A medication used to treat heartburn, indigestion, and ulcers in the gastrointestinal tract.

Clinical

An antacid used to treat various conditions in the GI tract, such as esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux.

Overview

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.

Magnesium oxide: absorbed Mg ions (up to... Read more

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Magaldrate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1alpha-Hydroxyvitamin D5
The serum concentration of Magaldrate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2
The serum concentration of Magaldrate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
2,5-Dimethoxy-4-ethylamphetamine
The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be increased when it is combined with Magaldrate.
2,5-Dimethoxy-4-ethylthioamphetamine
The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when it is combined with Magaldrate.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Magaldrate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-Bromo-2,5-dimethoxyamphetamine
The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be increased when it is combined with Magaldrate.
Abafungin
Magaldrate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acepromazine
Magaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aceprometazine
Magaldrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetaminophen
Magaldrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetophenazine
Magaldrate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigoxin
The serum concentration of Acetyldigoxin can be decreased when it is combined with Magaldrate.
Agmatine
The risk or severity of hypotension can be increased when Agmatine is combined with Magaldrate.
Albaconazole
Magaldrate can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aldosterone
The bioavailability of Aldosterone can be decreased when combined with Magaldrate.
Alendronic acid
The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.
Alfacalcidol
The serum concentration of Magaldrate can be increased when it is combined with Alfacalcidol.
Alimemazine
Magaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Allopurinol
The therapeutic efficacy of Allopurinol can be decreased when used in combination with Magaldrate.
Amiodarone
The risk or severity of hypotension can be increased when Amiodarone is combined with Magaldrate.
2 References
  1. 1 . Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6.PubMed: 8462913
  2. 2 . Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4.PubMed: 1790087